Navigation Links
Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced two oral presentations from studies related to lead developmental product candidate, fidaxomicin, will be presented at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at the Vancouver Convention Center in Vancouver, British Columbia, Canada on October 21-24, 2010.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)"Efficacy and Safety of Fidaxomicin vs. Vancomycin in Clostridium difficile Infection in 2 Randomized Controlled Trials with 1105 Patients"Oral Presentation: Derrick Crook, M.D.Saturday, October 23, 2010 3:30pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1417 "Categorization of Patients in a Large Multicenter Study of Clostridium difficile Infection Using the ATLAS Bedside Scoring System, and Correlation with Both Cure and Recurrence"Oral Presentation: Mark A. Miller, M.D.Saturday, October 23, 2010 2:00pm Pacific TimeSession: 146 Oral Abstract Session: Clostridium difficilePresentation number: 1411About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI) and we recently initiated a rolling submission of our NDA filing to the FDA, and have filed a MAA to the EMA (Europe).  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea and we plan to have a NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global ... and joint development activities. , “Dr. Floyd’s career has spanned 30 years in ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
Breaking Biology News(10 mins):